FB-CT2 Includes Two Prospective, Multi-centre Studies With a Medical Device in Hospital Settings: a Randomized, Dual-arm, Open-label Pilot Study in Spain, Followed by a Single-arm, Non-randomized, Open-label International Pivotal Study

NCT ID: NCT06968364

Last Updated: 2025-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

457 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-10

Study Completion Date

2027-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the safety and the ability of a clinical investigation device (Cervisense TPTL) to predict the risk of spontaneous preterm birth in pregnant women with symptoms of threatened preterm labor (TPTL), between 28+0 and 36+6 weeks of gestation. The main questions it aims to answer are:

Does the Cervisense TPTL device predict spontaneous preterm birth within 7 days?

Is the device safe and technically reliable in a hospital setting?

Researchers will conduct a Pilot Study (randomized, dual-arm) followed by a Pivotal Study (single-arm) to assess technical feasibility and predictive performance.

Participants will undergo an intravaginal measurement of cervical stiffness using the Cervisense Intravaginal Probe. They will be followed for 14 days after the assessment to record delivery outcomes and any adverse events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study titled "Evaluation of the safety and the preterm birth predictive capacity of the clinical investigation device 'Cervisense TPTL': an international clinical study" is designed to assess both the safety and performance of the Cervisense TPTL device in predicting spontaneous preterm birth. It is being conducted across various Gynaecology, Obstetrics, and Emergency Services in hospitals throughout Spain and Germany.

Cervisense TPTL is the investigational product being evaluated. It includes two components: the Cervisense Intravaginal Probe V0.1, which measures cervical stiffness, and the Fine Birth algorithm, which combines the measurement with clinical data to assess the short-term risk of spontaneous preterm labor.

The device is intended for use in pregnant women showing symptoms of threatened preterm labor (TPTL), with intact amniotic membranes and a single fetus, between 28 weeks and 36 weeks plus 6 days of gestation. Its purpose is to determine the risk of spontaneous preterm birth within the following 7 days.

The clinical investigation is structured in two phases. The pilot study is a randomized, dual-arm, open-label, interventional, multi-centre study conducted in Spain. Participants are randomized 1:1 to receive either the standard of care or the Cervisense evaluation. The pivotal study is non-randomized and single-arm, also open-label and interventional, conducted at a larger scale across multiple centres in both Spain and Germany.

The main goal is to confirm that the device is safe to use and reliable in clinical settings. For safety, all adverse events associated with the use of the device are documented and analyzed in terms of severity, duration, and required intervention. Special attention is given to potential complications such as tissue trauma or infection. To ensure unbiased evaluation, a Clinical Events Committee and a Data Safety Monitoring Board have been established to independently review adverse events and guide study continuation.

Inclusion Criteria:

* Female ≥18 years
* Singleton pregnancy
* Live fetus, 28w+0d-36w+6d GA
* Intact membranes
* Cervical dilatation \<2 cm
* Signed informed consent
* Regular uterine contractions (≥8/60 min) (Pivotal only)

Exclusion Criteria:

* Latex allergy
* Prolapsed membranes
* Fetal malformation
* Fetal infection
* Vaginal bleeding (severe or persistent)
* Cervical cerclage
* Müllerian anomalies
* Pessary use
* Regular uterine contractions (reported by patient) (Pilot only)
* History of preterm birth or TPTL (Pilot only)
* Vasa/placenta previa (Pilot only)
* Gastrointestinal or urinary infections (Pivotal only)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Threatened Preterm Labor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cervisense

Cervisense arm: Cervisense Intravaginal Probe V0.1 cervical stiffness evaluation.

Group Type EXPERIMENTAL

Cervisense Intravaginal Probe V0.1 cervical stiffness evaluation.

Intervention Type DEVICE

The Cervisense Intravaginal Probe V0.1 measures cervical stiffness. It is an in-vivo predictive technology that, by using torsional waves, quantifies the mechanical properties (specifically the shear modulus, or resistance of the cervix to shear deformation (kPa), of cervical tissue with extremely high precision. Torsional wave is a type of mechanical wave characterized by a rotational motion and low energy levels (it uses 1000 times less energy than other mechanical waves such as ultrasound). These waves propagate through the tissue, and their propagation speed, which is related to the stiffness (waves propagate faster in stiffer tissues), is measured using piezoelectric sensors.

Control arm (only in Pilot Phase)

Control arm: Cervicometry measured with transvaginal ultrasound

Group Type ACTIVE_COMPARATOR

Transvaginal ultrasound

Intervention Type DEVICE

Cervicometry measured with transvaginal ultrasound

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cervisense Intravaginal Probe V0.1 cervical stiffness evaluation.

The Cervisense Intravaginal Probe V0.1 measures cervical stiffness. It is an in-vivo predictive technology that, by using torsional waves, quantifies the mechanical properties (specifically the shear modulus, or resistance of the cervix to shear deformation (kPa), of cervical tissue with extremely high precision. Torsional wave is a type of mechanical wave characterized by a rotational motion and low energy levels (it uses 1000 times less energy than other mechanical waves such as ultrasound). These waves propagate through the tissue, and their propagation speed, which is related to the stiffness (waves propagate faster in stiffer tissues), is measured using piezoelectric sensors.

Intervention Type DEVICE

Transvaginal ultrasound

Cervicometry measured with transvaginal ultrasound

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female ≥18 years
* Singleton pregnancy
* Live fetus, 28w+0d-36w+6d GA
* Intact membranes
* Cervical dilatation \<2 cm
* Signed informed consent
* Regular uterine contractions (≥8/60 min) (Pivotal only)

Exclusion Criteria

* Latex allergy
* Prolapsed membranes
* Fetal malformation
* Fetal infection
* Vaginal bleeding (severe or persistent)
* Cervical cerclage
* Müllerian anomalies
* Pessary use
* Regular uterine contractions (reported by patient) (Pilot only)
* History of preterm birth or TPTL (Pilot only)
* Vasa/placenta previa (Pilot only)
* Gastrointestinal or urinary infections (Pivotal only)
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ultrasound-Innovation Medtech, S.L.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

H. Universitario de A Coruña

A Coruña, , Spain

Site Status NOT_YET_RECRUITING

H. Clínic de Barcelona

Barcelona, , Spain

Site Status NOT_YET_RECRUITING

H. Sant Joan de Déu

Barcelona, , Spain

Site Status NOT_YET_RECRUITING

H. Vall d'Hebron

Barcelona, , Spain

Site Status NOT_YET_RECRUITING

H. Universitario de Basurto

Bilbao, , Spain

Site Status RECRUITING

H. Universitario de Cruces

Bilbao, , Spain

Site Status RECRUITING

H. Universitario de Donostia

Donostia / San Sebastian, , Spain

Site Status NOT_YET_RECRUITING

H. Universitario San Cecilio

Granada, , Spain

Site Status RECRUITING

H. Materno Infantil de Gran Canaria

Las Palmas de Gran Canaria, , Spain

Site Status NOT_YET_RECRUITING

H. General Universitario Gregorio Marañón

Madrid, , Spain

Site Status NOT_YET_RECRUITING

H. Universitario de Torrejón

Madrid, , Spain

Site Status RECRUITING

H. Universitario La Paz

Madrid, , Spain

Site Status NOT_YET_RECRUITING

H. Universitario de Málaga

Málaga, , Spain

Site Status NOT_YET_RECRUITING

H. Virgen Arrixaca

Murcia, , Spain

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alberto Maroto Ferrer

Role: CONTACT

+34 747 44 15 38

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nuria Valiño

Role: primary

+34 981 178 000

Teresa Cobo

Role: primary

+34 93 227 54 00

Sílvia Ferrero

Role: primary

+34 93 253 21 00

María del Mar Goya Canino

Role: primary

+34 934 893 000

Amelia Valladolid Urdangaray

Role: primary

+34 944 006 000

Jorge Burgos San Cristóbal

Role: primary

946 006 000

Miren Arrue Arrue

Role: primary

+34 943 007 000

Francisca Molina García

Role: primary

+34 958 02 43 43

Silvia de León Socorro

Role: primary

+34 928 444 000

Santiago García-Tizón Larroca

Role: primary

+34 91 586 80 00

Maria del Mar Gil Mira

Role: primary

+34 91 626 26 00

Marcos Javier Cuerva González

Role: primary

+34 91 727 70 00

Jesús Jiménez López

Role: primary

+34 951 290 000

José Eliseo Blanco Carnero

Role: primary

+34 968 36 95 00

References

Explore related publications, articles, or registry entries linked to this study.

Papiernik E, Bouyer J, Collin D, Winisdoerffer G, Dreyfus J. Precocious cervical ripening and preterm labor. Obstet Gynecol. 1986 Feb;67(2):238-42. doi: 10.1097/00006250-198602000-00014.

Reference Type BACKGROUND
PMID: 3945433 (View on PubMed)

Parra-Saavedra M, Gomez L, Barrero A, Parra G, Vergara F, Navarro E. Prediction of preterm birth using the cervical consistency index. Ultrasound Obstet Gynecol. 2011 Jul;38(1):44-51. doi: 10.1002/uog.9010.

Reference Type BACKGROUND
PMID: 21465603 (View on PubMed)

Molina FS, Pardo L, Munoz MD, Aiartzaguena A, Valladolid A, Blanco JE, Burgos J, Gil MM. Reproducibility and usability assessment of the novel Fine Birth device for threatened preterm labor diagnosis. Am J Obstet Gynecol MFM. 2023 Jul;5(7):100982. doi: 10.1016/j.ajogmf.2023.100982. Epub 2023 Apr 23.

Reference Type BACKGROUND
PMID: 37094638 (View on PubMed)

Melchor JC, Navas H, Marcos M, Iza A, De Diego M, Rando D, Melchor I, Burgos J. Predictive performance of PAMG-1 vs fFN test for risk of spontaneous preterm birth in symptomatic women attending an emergency obstetric unit: retrospective cohort study. Ultrasound Obstet Gynecol. 2018 May;51(5):644-649. doi: 10.1002/uog.18892. Epub 2018 Mar 26.

Reference Type BACKGROUND
PMID: 28850753 (View on PubMed)

Melchor JC, Khalil A, Wing D, Schleussner E, Surbek D. Prediction of preterm delivery in symptomatic women using PAMG-1, fetal fibronectin and phIGFBP-1 tests: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018 Oct;52(4):442-451. doi: 10.1002/uog.19119. Epub 2018 Sep 4.

Reference Type BACKGROUND
PMID: 29920825 (View on PubMed)

Masso P, Callejas A, Melchor J, Molina FS, Rus G. In Vivo Measurement of Cervical Elasticity on Pregnant Women by Torsional Wave Technique: A Preliminary Study. Sensors (Basel). 2019 Jul 24;19(15):3249. doi: 10.3390/s19153249.

Reference Type BACKGROUND
PMID: 31344796 (View on PubMed)

Jackson GM, Ludmir J, Bader TJ. The accuracy of digital examination and ultrasound in the evaluation of cervical length. Obstet Gynecol. 1992 Feb;79(2):214-8. doi: 10.3109/01443619209013646.

Reference Type BACKGROUND
PMID: 1731287 (View on PubMed)

Horinouchi T, Yoshizato T, Muto M, Fujii M, Kozuma Y, Shinagawa T, Morokuma S, Kakuma T, Ushijima K. Gestational age-related changes in shear wave speed of the uterine cervix in normal pregnancy at 12-35 weeks' gestation. J Perinat Med. 2019 May 27;47(4):393-401. doi: 10.1515/jpm-2018-0250.

Reference Type BACKGROUND
PMID: 30817303 (View on PubMed)

Holcomb WL Jr, Smeltzer JS. Cervical effacement: variation in belief among clinicians. Obstet Gynecol. 1991 Jul;78(1):43-5.

Reference Type BACKGROUND
PMID: 2047066 (View on PubMed)

Goldenberg RL, Mercer BM, Meis PJ, Copper RL, Das A, McNellis D. The preterm prediction study: fetal fibronectin testing and spontaneous preterm birth. NICHD Maternal Fetal Medicine Units Network. Obstet Gynecol. 1996 May;87(5 Pt 1):643-8. doi: 10.1016/0029-7844(96)00035-x.

Reference Type BACKGROUND
PMID: 8677060 (View on PubMed)

Carlson LC, Feltovich H, Palmeri ML, Dahl JJ, Munoz del Rio A, Hall TJ. Estimation of shear wave speed in the human uterine cervix. Ultrasound Obstet Gynecol. 2014 Apr;43(4):452-8. doi: 10.1002/uog.12555. Epub 2014 Mar 12.

Reference Type BACKGROUND
PMID: 23836486 (View on PubMed)

Callejas A, Gomez A, Faris IH, Melchor J, Rus G. Kelvin-Voigt Parameters Reconstruction of Cervical Tissue-Mimicking Phantoms Using Torsional Wave Elastography. Sensors (Basel). 2019 Jul 25;19(15):3281. doi: 10.3390/s19153281.

Reference Type BACKGROUND
PMID: 31349721 (View on PubMed)

BISHOP EH. PELVIC SCORING FOR ELECTIVE INDUCTION. Obstet Gynecol. 1964 Aug;24:266-8. No abstract available.

Reference Type BACKGROUND
PMID: 14199536 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FB-CT2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Detection of Preterm Labour by Cervical Length
NCT04104984 UNKNOWN EARLY_PHASE1